Protein lipidation in cancer: mechanisms, dysregulation and emerging drug targets

EW Tate, L Soday, AL de la Lastra, M Wang… - Nature Reviews …, 2024 - nature.com
Protein lipidation describes a diverse class of post-translational modifications (PTMs) that is
regulated by over 40 enzymes, targeting more than 1,000 substrates at over 3,000 sites …

[HTML][HTML] Mesenchymal stem cell-derived extracellular vesicles in Cancer Therapy Resistance: from Biology to Clinical Opportunity

C Shan, Y Liang, K Wang, P Li - International Journal of Biological …, 2024 - ncbi.nlm.nih.gov
Mesenchymal stem cells (MSCs) are a type of stromal cells characterized by their properties
of self-renewal and multi-lineage differentiation, which make them prominent in regenerative …

Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer

C Zhou, C Li, L Luo, X Li, K Jia, N He, S Mao, W Wang… - Cancer Cell, 2024 - cell.com
Summary KRAS G12D is the most frequently mutated oncogenic KRAS subtype in solid
tumors and remains undruggable in clinical settings. Here, we developed a high affinity …

Novel RAF‐directed approaches to overcome current clinical limits and block the RAS/RAF node

R Scardaci, E Berlinska, P Scaparone… - Molecular …, 2024 - Wiley Online Library
Mutations in the RAS–RAF–MEK–ERK pathway are frequent alterations in cancer and
RASopathies, and while RAS oncogene activation alone affects 19% of all patients and …

Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver

J Ros, C Vaghi, I Baraibar, N Saoudi González… - International Journal of …, 2024 - mdpi.com
Kirsten rat sarcoma virus oncogene homolog (KRAS) is the most frequently mutated
oncogene in human cancer. In colorectal cancer (CRC), KRAS mutations are present in …

Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene—A Literature Review and Single-Center …

AK Rekowska, P Rola, A Kwiatkowska… - Biomedicines, 2024 - mdpi.com
Mutations in the KRAS gene are among the most common mutations observed in cancer
cells, but they have only recently become an achievable goal for targeted therapies. Two …

Small molecular inhibitors: Therapeutic strategies for pancreatic cancer

Y Golivi, S Kumari, B Farran, A Alam, S Peela… - Drug Discovery …, 2024 - Elsevier
Pancreatic cancer (PC), a disease with high heterogeneity and a dense stromal
microenvironment, presents significant challenges and a bleak prognosis. Recent …

Site-specific mutagenesis screening in KRASG12D mutant library to uncover resistance mechanisms to KRASG12D inhibitors

J Choi, J Shin, TK Kim, K Kim, J Kim, E Jeon, J Park… - Cancer Letters, 2024 - Elsevier
KRAS plays a crucial role in regulating cell survival and proliferation and is one of the most
commonly mutated oncogenes in human cancers. The novel KRAS G12D inhibitor …

Prognostic and predictive biomarkers in non-small cell lung carcinoma

I Odintsov, LM Sholl - Pathology, 2023 - Elsevier
Lung cancer is the most common cause of cancer-related deaths globally, with the highest
mortality rates among both men and women. Most lung cancers are diagnosed at late …

Antitumor effect of a small-molecule inhibitor of KRASG12D in xenograft models of mucinous appendicular neoplasms

MC Vázquez-Borrego, M Granados-Rodríguez… - … Hematology & Oncology, 2023 - Springer
Pseudomyxoma peritonei (PMP) is a rare disease characterized by a massive accumulation
of mucus in the peritoneal cavity. The only effective treatment is aggressive surgery, aimed …